

Where We Stand With Precision Therapeutics in Myeloma Pipedreams

Frontiers in Oncology

11, 819127

DOI: [10.3389/fonc.2021.819127](https://doi.org/10.3389/fonc.2021.819127)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2	Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
3	SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma. <i>Blood Advances</i> , 2023, 7, 469-481.	2.5	5
6	Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications. <i>Cytokine</i> , 2023, 161, 156062.	1.4	2
7	Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2645.	1.8	4
8	Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. <i>Cancers</i> , 2023, 15, 1508.	1.7	1